Please ensure Javascript is enabled for purposes of website accessibility

Gilead Antiviral Drug Shows the Most Potential for COVID-19, Says WHO Official

By Mark Prvulovic - Updated Feb 24, 2020 at 1:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Remdesivir looks promising as a treatment of the novel coronavirus' symptoms.

Gilead Sciences (GILD 4.85%) received a vote of confidence from the World Health Organization on Monday when a WHO official said that its experimental COVID-1) drug shows great potential.

Bruce Aylward, assistant director-general of the World Health Organization, went on to say during a Beijing briefing that remdesivir seems to be the "one drug right now that we think may have efficacy." Shares of Gilead shot up by as much as 6.9% following the briefing.

Microscopic depiction of coronavirus cells floating around.

Image source: Getty Images.

Remdesivir was originally developed to be an Ebola vaccine, but it proved less effective than was hoped against that disease. However, back in January, one COVID-19 patient who received remdesivir on a compassionate use basis saw a substantial improvement in symptoms. Since then, the Chinese government has started human trials with remdesivir, with WHO stating that clinical results would be available within weeks.

Analyst expectations

Although the COVID-19 epidemic is becoming a major worldwide issue, developing a treatment for it might not be all that lucrative. Geoff Meacham, an analyst at Bank of America, has said that remdesivir as a coronavirus treatment would have little long-term impact to Gilead's bottom line, at best bringing in $2.5 billion in one-time revenue for the biotech giant.

There are 79,737 confirmed cases of COVID-19 so far, with 2,628 deaths. While the virus' spread within China seems to have slowed down, other countries have seen a surge in cases. Italy reported another 66 cases of the coronavirus Monday, news that sent European stock markets into a panic.

Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$66.02 (4.85%) $3.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.